Showing 1 posts of 1 posts found.
Exscientia has launched Phase I trials in the US of DSP-0038 for the treatment of Alzheimer’s disease psychosis, the third …
MHRA approves first lower-carbon beclometasone inhalers for asthma
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide
Novogenia breaks ground on personalised healthcare campus
InfectoPharm launches Polish operations with first hospital antibiotic
FibroFind appoints Lee Borthwick as CEO